Matrix metalloproteinases and their inhibitors in different acute stroke subtypes

被引:42
作者
Vukasovic, I
Tesija-Kuna, A
Topic, E
Supanc, V
Demarin, V
Petrovcic, M
机构
[1] Univ Zagreb, Sestre Milosrdnice Univ Hosp, Inst Clin Chem, Zagreb 10000, Croatia
[2] Univ Zagreb, Sestre Milosrdnice Univ Hosp, Univ Dept Neurol, Zagreb 10000, Croatia
[3] Zagreb Zapad Hlth Ctr, Zagreb, Croatia
关键词
matrix metalloproteinases; stroke; tissue inhibitor of metalloproteinases;
D O I
10.1515/CCLM.2006.079
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The aim of the study was to determine serum levels of selected matrix metalloproteinases ( MMPs) and their natural inhibitors ( TIMPs) in the acute phase of different stroke types subdivided according to the Oxfordshire Community Stroke Project ( OCSP) classification and the possibility of discriminating stroke types according to their levels. The study included 126 patients with acute stroke within the first 24 h of symptom onset, and 124 healthy volunteers. The stroke group had lower MMP-2 concentrations and MMP-2/TIMP-2 ratios ( p<0.001) but higher TIMP-2 ( p<0.001) than controls. The level of MMP-9 and the MMP-9/TIMP-1 ratio were higher in patients with total anterior circulation infarct ( TACI) than in patients with other stroke subtypes according to OCSP classification ( p=0.0019, p=0.0065, respectively) or in controls ( p<0.0001, p=0.0024, respectively). A negative correlation of MMP-2 levels with MMP-9 and MMP-9/TIMP-1 ratio was recorded in all stroke subtypes except for TACI. Receiver operating characteristic analysis showed similar discriminating power for MMP-9 levels and Barthel index in the differential diagnosis of TACI. High MMP-9/TIMP-1 ratio ( odds ratio 3.263) was associated with TACI. Our results demonstrate that the MMP-9/TIMP-1 ratio may provide information to help in assessing stroke patients in the future as a baseline biomarker of infarct extent.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 36 条
[1]   Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood [J].
Alby, C ;
Ben Abdesselam, O ;
Foglietti, MJ ;
Beaudeux, JL .
CLINICA CHIMICA ACTA, 2002, 325 (1-2) :183-186
[2]   Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis [J].
Alvarez, B ;
Ruiz, C ;
Chacón, P ;
Alvarez-Sabin, J ;
Matas, M .
JOURNAL OF VASCULAR SURGERY, 2004, 40 (03) :469-475
[3]   Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage -: Relationship to clinical and radiological outcome [J].
Alvarez-Sabín, J ;
Delgado, P ;
Abilleira, S ;
Molina, CA ;
Arenillas, J ;
Ribó, M ;
Santamarina, E ;
Quintana, M ;
Monasterio, J ;
Montaner, J .
STROKE, 2004, 35 (06) :1316-1322
[4]   Blood-brain barrier disruption and matrix metalloproteinase-9 expression during, reperfusion injury - Mechanical versus embolic focal ischemia in spontaneously hypertensive rats [J].
Aoki, T ;
Sumii, T ;
Mori, T ;
Wang, XY ;
Lo, EH .
STROKE, 2002, 33 (11) :2711-2717
[5]   Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia [J].
Asahi, M ;
Wang, XY ;
Mori, T ;
Sumii, T ;
Jung, JC ;
Moskowitz, MA ;
Fini, ME ;
Lo, EH .
JOURNAL OF NEUROSCIENCE, 2001, 21 (19) :7724-7732
[6]   Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia [J].
Asahi, M ;
Sumii, T ;
Fini, ME ;
Itohara, S ;
Lo, EH .
NEUROREPORT, 2001, 12 (13) :3003-3007
[7]   Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes [J].
Avolio, C ;
Ruggieri, M ;
Giuliani, F ;
Liuzzi, GM ;
Leante, R ;
Riccio, P ;
Livrea, P ;
Trojano, M .
JOURNAL OF NEUROIMMUNOLOGY, 2003, 136 (1-2) :46-53
[8]   CLASSIFICATION AND NATURAL-HISTORY OF CLINICALLY IDENTIFIABLE SUBTYPES OF CEREBRAL INFARCTION [J].
BAMFORD, J ;
SANDERCOCK, P ;
DENNIS, M ;
BURN, J ;
WARLOW, C .
LANCET, 1991, 337 (8756) :1521-1526
[9]   Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives [J].
Beaudeux, JL ;
Giral, P ;
Bruckert, E ;
Foglietti, MJ ;
Chapman, MJ .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2004, 42 (02) :121-131
[10]   PROTEOLYTIC REMODELING OF EXTRACELLULAR-MATRIX [J].
BIRKEDALHANSEN, H .
CURRENT OPINION IN CELL BIOLOGY, 1995, 7 (05) :728-735